SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Baxter International, Inc. Announces Acquisition of All Hemophilia-Related Assets of Archemix Corporation and an Exclusive License of Its Anti-TFPI Aptamer Technology for $30 Million Upfront Plus Possible $285 Million More in Milestones